Trial reportCancer medicine2017
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Trial report in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- High frequency of brain metastases after adjuvant therapy for high-risk melanoma.Cancer medicine · 2017Trial
- Prevention of Brain Metastases: A New Frontier.Cancers · 2024Review
- Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011-2020).Journal of neuro-oncology · 2023Article
- Review
- Melanoma Brain Metastases: A Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment.Life (Basel, Switzerland) · 2023Review
- Metastatic Lesions of the Brain and Spine.Advances in experimental medicine and biology · 2023Article
- Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review.Cancers · 2022Review
- Melanoma therapeutics: a literature review.Journal of biomedical research · 2022Article
- Nanoparticle-Based Combination Therapy for Melanoma.Frontiers in oncology · 2022Review
- Prognostic factors following resection of intracranial metastases.Surgical neurology international · 2022Article
- Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.Journal of neuro-oncology · 2021Article
- Review
- A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases.Current oncology (Toronto, Ont.) · 2021Article
- Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance.Cancer medicine · 2020Observational
- The role of the immune system in brain metastasis.Current neurobiology · 2019Article
- Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma - final results of the BRAIN-RT trial.Cancer management and research · 2019Article
- Melanoma treatment in review.ImmunoTargets and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The incidence of CNS progression in patients with high-risk regional melanoma (stages IIIAN2a-IIIC) is not well characterized. Data from the S0008 trial provided an opportunity to examine the role of CNS progression in treatment failure and survival. All patients were surgically staged. Following wide excision and full regional lymphadenectomy, patients were randomized to receive adjuvant biochemotherapy (BCT) or high-dose interferon alfa-2B (HDI). CNS progression was retrospectively identified from data forms. Survival was measured from date of CNS progression. A total of 402 eligible patients were included in the analysis (BCT: 199, HDI: 203). Median follow-up (if alive) was over 7 years (range: 1 month to 11 years). The site of initial progression was identifiable in 80% of relapsing patients. CNS progression was a component of systemic melanoma relapse in 59/402 patients (15% overall). In 34/402 patients (9%) CNS progression represented the initial site of treatment failure. CNS progression was a component of initial progression in 27% of all patients whose melanoma relapsed (59/221). The risk of CNS progression was highest within 3 years of randomization. The difference in CNS progression rates between treatment arms was not significant (BCT = 25, HDI = 34, P = 0.24). Lymph node macrometastases strongly associated with CNS progression (P = 0.001), while ulceration and head and neck primaries were not significant predictors. This retrospective analysis of the S0008 trial identified a high brain metastasis rate (15%) in regionally advanced melanoma patients. Further studies are needed to establish whether screening plus earlier treatment would improve survival following CNS progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.